Phathom Pharmaceuticals, INC 8-K filings

Phathom Pharmaceuticals announced record Q2 2026 net revenues of $74.3 million, an 88% increase year-over-year, alongside a significant reduction in operating expenses and achievement of operating profitability excluding stock-based compensation.

Phathom Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of Class I directors and the ratification of its independent auditor.

Phathom Pharmaceuticals reported a 104% year-over-year increase in Q1 2026 net revenues to $58.3 million, while reducing operating expenses and maintaining full-year guidance with expected operating profitability in Q3 2026.

Phathom Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by significant VOQUEZNA revenue growth and strategic financial restructuring, projecting operating profitability by Q3 2026.

Phathom Pharmaceuticals announced the pricing of an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $130 million for general corporate purposes.

Phathom Pharmaceuticals announced preliminary unaudited financial results for Q4 and full year 2025, highlighting strong revenue and a milestone for VOQUEZNA.

Phathom Pharmaceuticals announced the dosing of the first patient in its Phase 2 pHalcon EoE-201 clinical trial for VOQUEZNA as a potential treatment for eosinophilic esophagitis in adults.

Phathom Pharmaceuticals reported strong third-quarter 2025 financial results, with net revenues up 25% quarter-over-quarter and reduced cash usage, advancing towards operating profitability in 2026.

Phathom Pharmaceuticals announces positive Phase 3 trial results for VOQUEZNA in treating nocturnal Non-Erosive Reflux Disease symptoms, published in a leading journal.

Phathom Pharmaceuticals, Inc. announced the appointment of Sanjeev Narula, a seasoned biopharmaceutical executive, as its new Chief Financial and Business Officer, effective October 6, 2025.

Phathom Pharmaceuticals announced robust second-quarter 2025 financial results, driven by significant VOQUEZNA prescription growth and a refined commercial strategy, reaffirming its path to profitability in 2026.

Phathom Pharmaceuticals, Inc. announced that the U.S. FDA has confirmed full 10-year New Chemical Entity exclusivity for its drug VOQUEZNA, extending its market protection until May 3, 2032.

Phathom Pharmaceuticals, Inc. announced the results of its 2025 Annual Meeting of Stockholders, confirming the re-election of two Class III directors, the ratification of Ernst & Young LLP as its independent auditor, and advisory approval of executive compensation.

Phathom Pharmaceuticals announced today that the FDA has approved its Citizen Petition, extending the New Chemical Entity exclusivity for its drug VOQUEZNA (vonoprazan) tablets by five years, now through May 3, 2032.

Phathom Pharmaceuticals announced its Q1 2025 financial results, highlighting VOQUEZNA launch momentum, strategic cost reductions, and leadership changes to achieve profitability in 2026.

Phathom Pharmaceuticals appoints Theodore R. Schroeder, a seasoned pharmaceutical executive, to its Board of Directors, effective April 16, 2025.

Phathom Pharmaceuticals announces the appointment of Steven Basta as CEO, effective April 1, 2025, following the resignation of Terrie Curran.

Phathom Pharmaceuticals announces its fourth quarter and full year 2024 financial results, highlighting $55.3 million in net revenue for VOQUEZNA's first full year and a Phase 2 EoE trial nearing initiation.

Phathom Pharmaceuticals has submitted a Citizen Petition to the FDA requesting a correction to the Orange Book listing for VOQUEZNA tablets to reflect a full 10-year New Chemical Entity exclusivity period.

Phathom Pharmaceuticals announced a significant increase in revenue and prescriptions for its GERD treatment, VOQUEZNA, in the third quarter of 2024, alongside expanded commercial access.

Phathom Pharmaceuticals has announced the pricing of a $130 million offering of common stock and pre-funded warrants to fund commercialization and clinical development.

Phathom Pharmaceuticals saw a significant increase in revenue and prescriptions for VOQUEZNA in the second quarter of 2024, driven by expanded FDA approvals and commercial coverage.

Phathom Pharmaceuticals announced FDA approval for VOQUEZNA 10 mg tablets to treat heartburn associated with Non-Erosive GERD in adults, marking its third approval for the drug.

Phathom Pharmaceuticals held its 2024 Annual Meeting of Stockholders, electing three Class II directors and ratifying its accounting firm, while also approving changes to its non-employee director compensation program.

Phathom Pharmaceuticals announced its first quarter 2024 financial results, highlighting a successful launch of VOQUEZNA with over 17,500 prescriptions dispensed and $1.9 million in net revenue.

Phathom Pharmaceuticals launched VOQUEZNA for Erosive GERD in November 2023, achieving $0.7 million in net revenue for the fourth quarter and securing expanded commercial coverage.

Phathom Pharmaceuticals announced that Express Scripts, a major U.S. pharmacy benefit manager, has added VOQUEZNA to its national formularies for commercial plans, effective immediately.